Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/100940
Title: | The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation |
Author: | Noriega, Victor Martínez-Laperche, Carolina Buces, Elena Pion, Marjorie Sánchez-Hernández, Noemí Martín-Antonio, Beatriz Guillem, Vicent Bosch-Vizcaya, Anna Bento, Leyre González Rivera, Milagros Balsalobre, Pascual Kwon, Mi Serrano, David Gayoso, Jorge Cámara, Rafael de la Brunet, Salut Rojas-Contreras, Rafael Nieto, José B. Martínez, Carmen Gónzalez, Marcos Espigado, Ildefonso Vallejo, Carlos Sampol, Antonia Jiménez-Velasco, Antonio Urbano Ispizua, Álvaro Solano, Carlos Gallardo, David Díez-Martín, José L. Buño, Ismael Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH) |
Keywords: | Limfòcits Cèl·lules T Cèl·lules mare Lymphocytes T cells Stem cells |
Issue Date: | 16-Oct-2015 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | The FOXP3 gene encodes for a protein (Foxp3) involved in the development and functional activity of regulatory T cells (CD4+/CD25+/Foxp3+), which exert regulatory and suppressive roles over the immune system. After allogeneic stem cell transplantation, regulatory T cells are known to mitigate graft versus host disease while probably maintaining a graft versus leukemia effect. Short alleles (≤(GT)15) for the (GT)n polymorphism in the promoter/enhancer of FOXP3 are associated with a higher expression of FOXP3, and hypothetically with an increase of regulatory T cell activity. This polymorphism has been related to the development of auto- or alloimmune conditions including type 1 diabetes or graft rejection in renal transplant recipients. However, its impact in the allo-transplant setting has not been analyzed. In the present study, which includes 252 myeloablative HLA-identical allo-transplants, multivariate analysis revealed a lower incidence of grade III-IV acute graft versus host disease (GVHD) in patients transplanted from donors harboring short alleles (OR = 0.26, CI 0.08-0.82, p = 0.021); without affecting chronic GVHD or graft versus leukemia effect, since cumulative incidence of relapse, event free survival and overall survival rates are similar in both groups of patients. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0140454 |
It is part of: | PLoS One, 2015, vol. 10, num. 10 |
URI: | http://hdl.handle.net/2445/100940 |
Related resource: | http://dx.doi.org/10.1371/journal.pone.0140454 |
ISSN: | 1932-6203 |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
659974.pdf | 881.76 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License